C-reactive protein, inflammation, and cardiovascular disease: clinical update.
Year: 2005
Type: article
Abstract: Two-and-a-half years ago, we presented C-reactive protein (CRP) data from the Women's Health Study, a large prospective study of 30,000 healthy middle-aged women followed over 10 years for the occurrence of first-ever cardiovascular events (the final results of the Women's Health Study regarding the effects of aspirin and of vitamin E randomization have just been published [N Engl J Med 2005;352:1293–304 and JAMA 2005;294:56–65]). We showed that high-sensitivity CRP is a very good predictor of vascular events in this population. Moreover, CRP provides prognostic information beyond low-density lipids (LDL). We identified a unique population—low-LDL, high-CRP individuals —that otherwise might have been missed. This was the impetus for the JUPITER trial, which I'll mention later.
Source: Europe PMC (PubMed Central)
Author: Paul M Ridker
Institution: Brigham and Women's Hospital
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W180144476